Bold Therapeutics to Present Positive Interim Gastric and Biliary Tract Cancer Results at ASCO 2023 Annual Meeting

Posted on by

VANCOUVER, BC, June 1, 2023 /PRNewswire/ — Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, will be presenting positive interim results in advanced gastric and biliary tract cancer at the 2023 American Society of Clinical…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.